The central nervous system as a promising target to treat diabetes mellitus

Current Topics in Medicinal Chemistry

Volumn 12, Issue 19, 2012, Pages 2070-2081

  Donato, Jose ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Brain; Drugs; Hypothalamus; Insulin; Insulin resistance; Leptin

Indexed keywords

AMYLIN; BROMOCRIPTINE; FLAVONOID; GLUCAGON; INSULIN; KETONE; LEPTIN; LEPTIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MELANOCORTIN RECEPTOR AGONIST; NEUROPEPTIDE Y; NEUROTRANSMITTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROOPIOMELANOCORTIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; RESVERATROL; RIMONABANT; SUPPRESSOR OF CYTOKINE SIGNALING 3; TERPENOID; TRODUSQUEMINE;

ANXIETY; ARTICLE; CENTRAL NERVOUS SYSTEM; DEPRESSION; DIABETES MELLITUS; ENERGY BALANCE; GENETIC MANIPULATION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSURIA; HYPERGLYCEMIA; HYPERPHAGIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; SIDE EFFECT; STREPTOZOCIN DIABETES; SUICIDE; SURVIVAL;

EID: 84874851044     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612804910214     Document Type: Article

References (164)

1. Havrankova, J.; Roth, J.; Brownstein, M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature, 1978, 272, 827-829.
2. Marks, J.L.; Porte, D.; Stahl, W.L.; Baskin, D.G. Localization of insulin receptor mRNA in rat brain by in situ hybridization. Endocrinology, 1990, 127, 3234-3236.
3. Chen, M.; Woods, S.C.; Porte, D., Jr. Effect of cerebral intraventricular insulin on pancreatic insulin secretion in the dog. Diabetes, 1975, 24, 910-914.
4. Obici, S.; Zhang, B.B.; Karkanias, G.; Rossetti, L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med, 2002, 8, 1376-1382.
5. Brüning, J.C.; Gautam, D.; Burks, D.J.; Gillette, J.; Schubert, M.; Orban, P.C.; Klein, R.; Krone, W.; Müller-Wieland, D.; Kahn, C.R. Role of Brain Insulin Receptor in Control of Body Weight and Reproduction. Science, 2000, 289, 2122-2125.
6. Koch, L.; Wunderlich, F.T.; Seibler, J.; Konner, A.C.; Hampel, B.; Irlenbusch, S.; Brabant, G.; Kahn, C.R.; Schwenk, F.; Bruning, J.C. Central insulin action regulates peripheral glucose and fat metabolism in mice. J Clin Invest, 2008,
7. Yue, Jessicat Y.; Lam, Tony k.T. Lipid Sensing and Insulin Resistance in the Brain. Cell Metabolism, 2012, 15, 646-655.
8. De Souza, C.T.; Araujo, E.P.; Bordin, S.; Ashimine, R.; Zollner, R.L.; Boschero, A.C.; Saad, M.J.A.; Velloso, L.A. Consumption of a Fat-Rich Diet Activates a Proinflammatory Response and Induces Insulin Resistance in the Hypothalamus. Endocrinology, 2005, 146, 4192-4199.
9. Chick, W.L.; Lavine, R.L.; Like, A.A. Studies in the diabetic mutant mouse. V. Glucose tolerance in mice homozygous and heterozygous for the diabetes (db) gene. Diabetologia, 1970, 6, 257-262.
10. Chen, H.; Charlat, O.; Tartaglia, L.A.; Woolf, E.A.; Weng, X.; Ellis, S.J.; Lakey, N.D.; Culpepper, J.; More, K.J.; Breitbart, R.E.; Duyk, G.M.; Tepper, R.I.; Morgenstern, J.P. Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice. Cell, 1996, 84, 491-495.
11. Lee, G.-H.; Proenca, R.; Montez, J.M.; Carroll, K.M.; Darvishzadeh, J.G.; Lee, J.I.; Friedman, J.M. Abnormal splicing of the leptin receptor in diabetic mice. Nature, 1996, 379, 632-635.
12. Chua, S.C.; Chung, W.K.; Wu-Peng, X.S.; Zhang, Y.; Liu, S.-M.; Tartaglia, L.; Leibel, R.L. Phenotypes of Mouse diabetes and Rat fatty Due to Mutations in the OB (Leptin) Receptor. Science, 1996, 271, 994-996.
13. Zhang, Y.; Proenca, R.; Maffei, M.; Barone, M.; Leopold, L.; Friedman, J.M. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994, 372, 425-432.
14. Cohen, P.; Zhao, C.; Cai, X.; Montez, J.M.; Rohani, S.C.; Feinstein, P.; Mombaerts, P.; Friedman, J.M. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest, 2001, 108, 1113-1121.
15. De Luca, C.; Kowalski, T.J.; Zhang, Y.; Elmquist, J.K.; Lee, C.; Kilimann, M.W.; Ludwig, T.; Liu, S.M.; Chua, S.C., Jr. Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenes. J Clin Invest, 2005, 115, 3484-3493.
16. Kowalski, T.J.; Liu, S.M.; Leibel, R.L.; Chua, S.C., Jr. Transgenic complementation of leptin-receptor deficiency. I. Rescue of the obesity/diabetes phenotype of LEPR-null mice expressing a LEPRB transgene. Diabetes, 2001, 50, 425-435.
17. Coppari, R.; Ichinose, M.; Lee, C.E.; Pullen, A.E.; Kenny, C.D.; Mcgovern, R.A.; Tang, V.; Liu, S.M.; Ludwig, T.; Chua, S.C., Jr.; Lowell, B.B.; Elmquist, J.K. The hypothalamic arcuate nucleus: a key site for mediating leptin's effects on glucose homeostasis and locomotor activity. Cell Metab, 2005, 1, 63-72.
18. Berglund, E.D.; Vianna, C.R.; Donato, J., Jr.; Kim, M.H.; Chuang, J.C.; Lee, C.E.; Lauzon, D.A.; Lin, P.; Brule, L.J.; Scott, M.M.; Coppari, R.; Elmquist, J.K. Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest, 2012, 122, 1000-1009.
19. Huo, L.; Gamber, K.; Greeley, S.; Silva, J.; Huntoon, N.; Leng, X.H.; Bjorbaek, C. Leptin-dependent control of glucose balance and locomotor activity by POMC neurons. Cell Metabolism, 2009, 9, 537-547.
20. Pelleymounter, M.A.; Cullen, M.J.; Baker, M.B.; Hecht, R.; Winters, D.; Boone, T.; Collins, F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science, 1995, 269, 540-543.
21. Kamohara, S.; Burcelin, R.; Halaas, J.L.; Friedman, J.M.; Charron, M.J. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature, 1997, 389, 374-377.
22. Scott, M.M.; Lachey, J.L.; Sternson, S.M.; Lee, C.E.; Elias, C.F.; Friedman, J.M.; Elmquist, J.K. Leptin targets in the mouse brain. J Comp Neurol, 2009, 514, 518-532.
23. Morton, G.J.; Gelling, R.W.; Niswender, K.D.; Morrison, C.D.; Rhodes, C.J.; Schwartz, M.W. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metabolism, 2005, 2, 411-420.
24. Könner, A.C.; Janoschek, R.; Plum, L.; Jordan, S.D.; Rother, E.; Ma, X.; Xu, C.; Enriori, P.; Hampel, B.; Barsh, G.S.; Kahn, C.R.; Cowley, M.A.; Ashcroft, F.M.; Brüning, J.C. Insulin Action in AgRP-Expressing Neurons Is Required for Suppression of Hepatic Glucose Production. Cell Metabolism, 2007, 5, 438-449.
25. Elmquist, J.K.; Coppari, R.; Balthasar, N.; Ichinose, M.; Lowell, B.B. Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol, 2005, 493, 63-71.
26. Schwartz, M.W.; Woods, S.C.; Porte, D., Jr.; Seeley, R.J.; Baskin, D.G. Central nervous system control of food intake. Nature, 2000, 404, 661-671.
27. Xu, Y.; Elmquist, J.K.; Fukuda, M. Central nervous control of energy and glucose balance: focus on the central melanocortin system. Annals of the New York Academy of Sciences, 2011, 1243, 1-14.
28. Erickson, J.C.; Hollopeter, G.; Palmiter, R.D. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science, 1996, 274, 1704-1707.
29. Sindelar, D.K.; Mystkowski, P.; Marsh, D.J.; Palmiter, R.D.; Schwartz, M.W. Attenuation of Diabetic Hyperphagia in Neuropeptide Y-Deficient Mice. Diabetes, 2002, 51, 778-783.
30. Huszar, D.; Lynch, C.A.; Fairchild-Huntress, V.; Dunmore, J.H.; Fang, Q.; Berkemeier, L.R.; Gu, W.; Kesterson, R.A.; Boston, B.A.; Cone, R.D.; Smith, F.J.; Campfield, L.A.; Burn, P.; Lee, F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell, 1997, 88, 131-141.
31. Farooqi, I.S.; Keogh, J.M.; Yeo, G.S.; Lank, E.J.; Cheetham, T.; O'rahilly, S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med, 2003, 348, 1085-1095.
32. Farooqi, S.; O'rahilly, S. Genetics of obesity in humans. Endocr Rev, 2006, 27, 710-718.
33. Obici, S.; Feng, Z.; Tan, J.; Liu, L.; Karkanias, G.; Rossetti, L. Central melanocortin receptors regulate insulin action. J Clin Invest, 2001, 108, 1079-1085.
34. Fan, W.; Dinulescu, D.M.; Butler, A.A.; Zhou, J.; Marks, D.L.; Cone, R.D. The Central Melanocortin System Can Directly Regulate Serum Insulin Levels. Endocrinology, 2000, 141, 3072-3079.
35. Williams, K.W.; Margatho, L.O.; Lee, C.E.; Choi, M.; Lee, S.; Scott, M.M.; Elias, C.F.; Elmquist, J.K. Segregation of Acute Leptin and Insulin Effects in Distinct Populations of Arcuate Proopiomelanocortin Neurons. J Neurosci, 2010, 30, 2472-2479.
36. Spanswick, D.; Smith, M.A.; Groppi, V.E.; Logan, S.D.; Ashford, M.L. Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels. Nature, 1997, 390, 521-525.
37. Spanswick, D.; Smith, M.A.; Mirshamsi, S.; Routh, V.H.; Ashford, M.L. Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats. Nat Neurosci, 2000, 3, 757-758.
38. Plum, L.; Ma, X.; Hampel, B.; Balthasar, N.; Coppari, R.; Münzberg, H.; Shanabrough, M.; Burdakov, D.; Rother, E.; Janoschek, R.; Alber, J.; Belgardt, B.F.; Koch, L.; Seibler, J.; Schwenk, F.; Fekete, C.; Suzuki, A.; Mak, T.W.; Krone, W.; Horvath, T.L.; Ashcroft, F.M.; Brüning, J.C. Enhanced PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive obesity. The Journal of Clinical Investigation, 2006, 116, 1886-1901.
39. Pocai, A.; Lam, T.K.T.; Gutierrez-Juarez, R.; Obici, S.; Schwartz, G.J.; Bryan, J.; Aguilar-Bryan, L.; Rossetti, L. Hypothalamic KATP channels control hepatic glucose production. Nature, 2005, 434, 1026-1031.
40. Parton, L.E.; Ye, C.P.; Coppari, R.; Enriori, P.J.; Choi, B.; Zhang, C.Y.; Xu, C.; Vianna, C.R.; Balthasar, N.; Lee, C.E.; Elmquist, J.K.; Cowley, M.A.; Lowell, B.B. Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity. Nature, 2007, 449, 228-232.
41. Kishi, T.; Aschkenasi, C.J.; Lee, C.E.; Mountjoy, K.G.; Saper, C.B.; Elmquist, J.K. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J Comp Neurol, 2003, 457, 213-235.
42. Liu, H.; Kishi, T.; Roseberry, A.G.; Cai, X.; Lee, C.E.; Montez, J.M.; Friedman, J.M.; Elmquist, J.K. Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. J Neurosci, 2003, 23, 7143-7154.
43. Swanson, L.W.; Sawchenko, P.E. Paraventricular nucleus: a site for the integration of neuroendocrine and autonomic mechanisms. Neuroendocrinology, 1980, 31, 410-417.
44. Swanson, L.W.; Kuypers, H.G. The paraventricular nucleus of the hypothalamus: cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord as demonstrated by retrograde fluorescence double-labeling methods. J Comp Neurol, 1980, 194, 555-570.
45. Balthasar, N.; Dalgaard, L.T.; Lee, C.E.; Yu, J.; Funahashi, H.; Williams, T.; Ferreira, M.; Tang, V.; Mcgovern, R.A.; Kenny, C.D.; Christiansen, L.M.; Edelstein, E.; Choi, B.; Boss, O.; Aschkenasi, C.; Zhang, C.Y.; Mountjoy, K.; Kishi, T.; Elmquist, J.K.; Lowell, B.B. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell, 2005, 123, 493-505.
46. Toda, C.; Shiuchi, T.; Lee, S.; Yamato-Esaki, M.; Fujino, Y.; Suzuki, A.; Okamoto, S.; Minokoshi, Y. Distinct Effects of Leptin and a Melanocortin Receptor Agonist Injected Into Medial Hypothalamic Nuclei on Glucose Uptake in Peripheral Tissues. Diabetes, 2009, 58, 2757-2765.
47. Sudo, M.; Minokoshi, Y.; Shimazu, T. Ventromedial hypothalamic stimulation enhances peripheral glucose uptake in anesthetized rats. Am J Physiol, 1991, 261, E298-303.
48. Ziegler, D.R.; Cullinan, W.E.; Herman, J.P. Distribution of vesicular glutamate transporter mRNA in rat hypothalamus. The Journal of Comparative Neurology, 2002, 448, 217-229.
49. Tong, Q.; Ye, C.; Mccrimmon, R.J.; Dhillon, H.; Choi, B.; Kramer, M.D.; Yu, J.; Yang, Z.; Christiansen, L.M.; Lee, C.E.; Choi, C.S.; Zigman, J.M.; Shulman, G.I.; Sherwin, R.S.; Elmquist, J.K.; Lowell, B.B. Synaptic Glutamate Release by Ventromedial Hypothalamic Neurons Is Part of the Neurocircuitry that Prevents Hypoglycemia. Cell Metabolism, 2007, 5, 383-393.
50. Klockener, T.; Hess, S.; Belgardt, B.F.; Paeger, L.; Verhagen, L.A.W.; Husch, A.; Sohn, J.-W.; Hampel, B.; Dhillon, H.; Zigman, J.M.; Lowell, B.B.; Williams, K.W.; Elmquist, J.K.; Horvath, T.L.; Kloppenburg, P.; Bruning, J.C. High-fat feeding promotes obesity via insulin receptor/PI3K-dependent inhibition of SF-1 VMH neurons. Nat Neurosci, 2011, 14, 911-918.
51. Bingham, N.C.; Anderson, K.K.; Reuter, A.L.; Stallings, N.R.; Parker, K.L. Selective loss of leptin receptors in the ventromedial hypothalamic nucleus results in increased adiposity and a metabolic syndrome. Endocrinology, 2008, 149, 2138-2148.
52. Kong, D.; Vong, L.; Parton, L.E.; Ye, C.; Tong, Q.; Hu, X.; Choi, B.; Brüning, J.C.; Lowell, B.B. Glucose Stimulation of Hypothalamic MCH Neurons Involves KATP Channels, Is Modulated by UCP2, and Regulates Peripheral Glucose Homeostasis. Cell Metabolism, 2010, 12, 545-552.
53. Marino, J.S.; Xu, Y.; Hill, J.W. Central insulin and leptin-mediated autonomic control of glucose homeostasis. Trends in Endocrinology & Metabolism, 2011, 22, 275-285.
54. Shimazu, T. Regulation of glycogen metabolism in liver by the autonomic nervous system. V. Activation of glycogen synthetase by vagal stimulation. Biochim Biophys Acta, 1971, 252, 28-38.
55. Shimazu, T.; Amakawa, A. Regulation of glycogen metabolism in liver by the autonomic nervous system. 3. Differential effects of sympathetic-nerve stimulation and of catecholamines on liver phosphorylase. Biochim Biophys Acta, 1968, 165, 349-356.
56. Matsuhisa, M.; Yamasaki, Y.; Shiba, Y.; Nakahara, I.; Kuroda, A.; Tomita, T.; Iida, M.; Ikeda, M.; Kajimoto, Y.; Kubota, M.; Hori, M. Important role of the hepatic vagus nerve in glucose uptake and production by the liver. Metabolism, 2000, 49, 11-16.
57. Van Den Hoek, A.M.; Van Heijningen, C.; Schroder Van Der Elst, J.P.; Ouwens, D.M.; Havekes, L.M.; Romijn, J.A.; Kalsbeek, A.; Pijl, H. Intracerebroventricular administration of neuropeptide Y induces hepatic insulin resistance via sympathetic innervation. Diabetes, 2008, 57, 2304-2310.
58. Gautron, L.; Lee, C.; Funahashi, H.; Friedman, J.; Lee, S.; Elmquist, J. Melanocortin-4 receptor expression in a vago-vagal circuitry involved in postprandial functions. J Comp Neurol, 2010, 518, 6-24.
59. Rossi, J.; Balthasar, N.; Olson, D.; Scott, M.; Berglund, E.; Lee, C.E.; Choi, M.J.; Lauzon, D.; Lowell, B.B.; Elmquist, J.K. Melanocortin-4 Receptors Expressed by Cholinergic Neurons Regulate Energy Balance and Glucose Homeostasis. Cell Metabolism, 2011, 13, 195-204.
60. Cincotta, A.H.; Meier, A.H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care, 1996, 19, 667-670.
61. Pijl, H.; Ohashi, S.; Matsuda, M.; Miyazaki, Y.; Mahankali, A.; Kumar, V.; Pipek, R.; Iozzo, P.; Lancaster, J.L.; Cincotta, A.H.; Defronzo, R.A. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care, 2000, 23, 1154-1161.
62. Kamath, V.; Jones, C.N.; Yip, J.C.; Varasteh, B.B.; Cincotta, A.H.; Reaven, G.M.; Chen, Y.D. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care, 1997, 20, 1697-1701.
63. Barnett, A.H.; Chapman, C.; Gailer, K.; Hayter, C.J. Effect of bromocriptine on maturity onset diabetes. Postgraduate medical journal, 1980, 56, 11-14.
64. Holt, R.I.G.; Barnett, A.H.; Bailey, C.J. Bromocriptine: old drug, new formulation and new indication. Diabetes, Obesity and Metabolism, 2010, 12, 1048-1057.
65. Berinder, K.; Nystrom, T.; Hoybye, C.; Hall, K.; Hulting, A.L. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary, 2011, 14, 199-207.
66. Gibson, C.D.; Karmally, W.; Mcmahon, D.J.; Wardlaw, S.L.; Korner, J. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes, Obesity and Metabolism, 2012, 14, 335-340.
67. Valiquette, G. Bromocriptine for Diabetes Mellitus Type II. Cardiology in Review, 2011, 19, 272-275.
68. Luo, S.; Meier, A.H.; Cincotta, A.H. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology, 1998, 68, 1-10.
69. Bina, K.G.; Cincotta, A.H. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology, 2000, 71, 68-78.
70. Scislowski, P.W.; Tozzo, E.; Zhang, Y.; Phaneuf, S.; Prevelige, R.; Cincotta, A.H. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes Relat Metab Disord, 1999, 23, 425-431.
71. Liang, Y.; Lubkin, M.; Sheng, H.; Scislowski, P.W.; Cincotta, A.H. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice. Biochim Biophys Acta, 1998, 1405, 1-13.
72. Cincotta, A.H.; Tozzo, E.; Scislowski, P.W. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci, 1997, 61, 951-956.
73. Liang, Y.; Jetton, T.L.; Lubkin, M.; Meier, A.H.; Cincotta, A.H. Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cellular and molecular life sciences: CMLS, 1998, 54, 703-711.
74. Luo, S.; Liang, Y.; Cincotta, A.H. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology, 1999, 69, 160-166.
75. Lee, H.K.; Choi, E.B.; Pak, C.S. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Current topics in medicinal chemistry, 2009, 9, 482-503.
76. Wu, Y.K.; Yeh, C.F.; Ly, T.W.; Hung, M.S. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier. Current topics in medicinal chemistry, 2011, 11, 1421-1429.
77. O'hare, J.D.; Zielihski, E.; Cheng, B.; Scherer, T.; Buettner, C. Central Endocannabinoid Signaling Regulates Hepatic Glucose Production and Systemic Lipolysis. Diabetes, 2011, 60, 1055-1062.
78. Daneman, D. Type 1 diabetes. The Lancet, 367, 847-858.
79. Unger, R.H.; Cherrington, AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest, 2012, 122, 4-12.
80. Raskin, P.; Unger, R.H. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Engl J Med, 1978, 299, 433-436.
81. Gerich, J.E.; Lorenzi, M.; Bier, D.M.; Schneider, V.; Tsalikian, E.; Karam, J.H.; Forsham, P.H. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med, 1975, 292, 985-989.
82. Liljenquist, J.E.; Mueller, G.L.; Cherrington, A.D.; Keller, U.; Chiasson, J.L.; Perry, J.M.; Lacy, W.W.; Rabinowitz, D. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. The Journal of Clinical Investigation, 1977, 59, 369-374.
83. Lee, Y.; Wang, M.-Y.; Du, X.Q.; Charron, M.J.; Unger, R.H. Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice. Diabetes, 2011, 60, 391-397.
84. Tudurí, E.; Marroquí, L.; Soriano, S.; Ropero, A.B.; Batista, T.M.; Piquer, S.; López-Boado, M.A.; Carneiro, E.M.; Gomis, R.; Nadal, A.; Quesada, I. Inhibitory Effects of Leptin on Pancreatic a-Cell Function. Diabetes, 2009, 58, 1616-1624.
85. German, J.P.; Wisse, B.E.; Thaler, J.P.; Oh IS.; Sarruf, D.A.; Ogimoto, K.; Kaiyala, K.J.; Fischer, J.D.; Matsen, M.E.; Taborsky, G.J.; Schwartz, M.W.; Morton, G.J. Leptin Deficiency Causes Insulin Resistance Induced by Uncontrolled Diabetes. Diabetes, 2010, 59, 1626-1634.
86. Denroche, H.C.; Levi, J.; Wideman, R.D.; Sequeira, R.M.; Huynh, F.K.; Covey, S.D.; Kieffer, T.J. Leptin Therapy Reverses Hyperglycemia in Mice With Streptozotocin-Induced Diabetes, Independent of Hepatic Leptin Signaling. Diabetes, 2011, 60, 1414-1423.
87. Naito, M.; Fujikura, J.; Ebihara, K.; Miyanaga, F.; Yokoi, H.; Kusakabe, T.; Yamamoto, Y.; Son, C; Mukoyama, M.; Hosoda, K.; Nakao, K. Therapeutic Impact of Leptin on Diabetes, Diabetic Complications, and Longevity in Insulin-Deficient Diabetic Mice. Diabetes, 2011, 60, 2265-2273.
88. Wang, M.-Y.; Chen, L.; Clark, G.O.; Lee, Y.; Stevens, R.D.; Ilkayeva, O.R.; Wenner, B.R.; Bain, J.R.; Charron, M.J.; Newgard, C.B.; Unger, R.H. Leptin therapy in insulin-deficient type I diabetes. Proceedings of the National Academy of Sciences, 2010, 107, 4813-4819.
89. Fujikawa, T.; Chuang, J.-C; Sakata, I.; Ramadori, G.; Coppari, R. Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proceedings of the National Academy of Sciences, 2010, 107, 17391-17396.
90. Mizuno, A.; Murakami, T.; Otani, S.; Kuwajima, M.; Shima, K. Leptin Affects Pancreatic Endocrine Functions through the Sympathetic Nervous System. Endocrinology, 1998, 139, 3863-3870.
91. Shimomura, I.; Hammer, R.E.; Ikemoto, S.; Brown, M.S.; Goldstein, J.L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature, 1999, 401, 73-76.
92. Javor, E.D.; Cochran, E.K.; Musso, C.; Young, J.R.; Depaoli, A.M.; Gorden, P. Long-Term Efficacy of Leptin Replacement in Patients With Generalized Lipodystrophy. Diabetes, 2005, 54, 1994-2002.
93. Petersen, K.F.; Oral, E.A.; Dufour, S.; Befroy, D.; Ariyan, C.; Yu, C.; Cline, G.W.; Depaoli, A.M.; Taylor, S.I.; Gorden, P.; Shulman, G.I. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest, 2002, 109, 1345-1350.
94. Oral, E.A.; Simha, V.; Ruiz, E.; Andewelt, A.; Premkumar, A.; Snell, P.; Wagner, A.J.; Depaoli, A.M.; Reitman, M.L.; Taylor, S.I.; Gorden, P.; Garg, A. Leptin-Replacement Therapy for Lipodystrophy. New England Journal of Medicine, 2002, 346, 570-578.
95. Asilmaz, E.; Cohen, P.; Miyazaki, M.; Dobrzyn, P.; Ueki, K.; Fayzikhodjaeva, G.; Soukas, A.A.; Kahn, C.R.; Ntambi, J.M.; Socci, N.D.; Friedman, J.M. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest, 2004, 113, 414-424.
96. Lee, J.H.; Chan, J.L.; Sourlas, E.; Raptopoulos, V.; Mantzoros, C.S. Recombinant Methionyl Human Leptin Therapy in Replacement Doses Improves Insulin Resistance and Metabolic Profile in Patients with Lipoatrophy and Metabolic Syndrome Induced by the Highly Active Antiretroviral Therapy. Journal of Clinical Endocrinology & Metabolism, 2006, 91, 2605-2611.
97. Dhuria, S.V.; Hanson, L.R.; Frey, W.H. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. Journal of Pharmaceutical Sciences, 2010, 99, 1654-1673.
98. Salzman, R.; Manson, J.E.; Griffing, G.T.; Kimmerle, R.; Ruderman, N.; Mccall, A.; Stoltz, E.I.; Mullin, C.; Small, D.; Armstrong, J.; Melby, J.C. Intranasal Aerosolized Insulin. New England Journal of Medicine, 1985, 312, 1078-1084.
99. Woods, S.C.; Lotter, E.C.; Mckay, L.D.; Porte, D., Jr. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature, 1979, 282, 503-505.
100. Lotter, E.C.; Woods, S.C. Injections of insulin and changes of body weight. Physiol Behav, 1977, 18, 293-297.
101. Porte, D., Jr.; Woods, S.C. Regulation of food intake and body weight in insulin. Diabetologia, 1981, 20 Suppl, 274-280.
102. Hallschmid, M.; Benedict, C.; Schultes, B.; Fehm, H.-L.; Born, J.; Kern, W. Intranasal Insulin Reduces Body Fat in Men but not in Women. Diabetes, 2004, 53, 3024-3029.
103. Hallschmid, M.; Higgs, S.; Thienel, M.; Ott, V.; Lehnert, H. Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women. Diabetes, 2012, 61, 782-789.
104. Jauch-Chara, K.; Friedrich, A.; Rezmer, M.; Melchert, U.H.; Scholand-Engler, H.G.; Hallschmid, M.; Oltmanns, K.M. Intranasal Insulin Suppresses Food Intake via Enhancement of Brain Energy Levels in Humans. Diabetes, 2012,
105. Schioth, H.B.; Frey, W.H.; Brooks, S.J.; Benedict, C. Insulin to treat Alzheimer's disease: just follow your nose? Expert review of clinical pharmacology, 2012, 5, 17-20.
106. Ott, V.; Benedict, C.; Schultes, B.; Born, J.; Hallschmid, M. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes, obesity & metabolism, 2012, 14, 214-221.
107. Benedict, C.; Hallschmid, M.; Schultes, B.; Born, J.; Kern, W. Intranasal insulin to improve memory function in humans. Neuroendocrinology, 2007, 86, 136-142.
108. Shemesh, E.; Rudich, A.; Harman-Boehm, I.; Cukierman-Yaffe, T. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab, 2012, 97, 366-376.
109. Thorne, R.G.; Pronk, G.J.; Padmanabhan, V.; Frey Ii, W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience, 2004, 127, 481-496.
110. Chen, X.Q.; Fawcett, J.R.; Rahman, Y.E.; Ala, T.A.; Frey, I.W. Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. Journal of Alzheimer's disease: JAD, 1998, 1, 35-44.
111. Nonaka, N.; Farr, S.A.; Kageyama, H.; Shioda, S.; Banks, W.A. Delivery of Galanin-Like Peptide to the Brain: Targeting with Intranasal Delivery and Cyclodextrins. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 513-519.
112. Howard, J.K.; Flier, J.S. Attenuation of leptin and insulin signaling by SOCS proteins. Trends in Endocrinology & Metabolism, 2006, 17, 365-371.
113. Morris, D.L.; Rui, L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab, 2009, 297, E1247-1259.
114. Bjorbaek, C.P. Central Leptin Receptor Action and Resistance in Obesity. Journal of Investigative Medicine, 2009, 57, 789-794.
115. Myers, M.G.; Cowley, M.A.; Munzberg, H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol, 2008, 70, 537-556.
116. Briancon, N.; Mcnay, D.E.; Maratos-Flier, E.; Flier, J.S. Combined Neural Inactivation of Suppressor of Cytokine Signaling-3 and Protein-Tyrosine Phosphatase-1B Reveals Additive, Synergistic, and Factor-Specific Roles in the Regulation of Body Energy Balance. Diabetes, 2010, 59, 3074-3084.
117. Klaman, L.D.; Boss, O.; Peroni, O.D.; Kim, J.K.; Martino, J.L.; Zabolotny, J.M.; Moghal, N.; Lubkin, M.; Kim, Y.-B.; Sharpe, A.H.; Stricker-Krongrad, A.; Shulman, G.I.; Neel, B.G.; Kahn, B.B. Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-Deficient Mice. Mol Cell Biol, 2000, 20, 5479-5489.
118. Kaszubska, W.; Falls, H.D.; Schaefer, V.G.; Haasch, D.; Frost, L.; Hessler, P.; Kroeger, P.E.; White, D.W.; Jirousek, M.R.; Trevillyan, J.M. Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line. Molecular and Cellular Endocrinology, 2002, 195, 109-118.
119. Zabolotny, J.M.; Bence-Hanulec, K.K.; Stricker-Krongrad, A.; Haj, F.; Wang, Y.; Minokoshi, Y.; Kim, Y.B.; Elmquist, J.K.; Tartaglia, L.A.; Kahn, B.B.; Neel, B.G. PTP1B regulates leptin signal transduction in vivo. Dev Cell, 2002, 2, 489-495.
120. Bence, K.K.; Delibegovic, M.; Xue, B.; Gorgun, C.Z.; Hotamisligil, G.S.; Neel, B.G.; Kahn, B.B. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med, 2006, 12, 917-924.
121. Sun, C.; Zhang, F.; Ge, X.; Yan, T.; Chen, X.; Shi, X.; Zhai, Q. SIRT1 Improves Insulin Sensitivity under Insulin-Resistant Conditions by Repressing PTP1B. Cell Metab, 2007, 6, 307-319.
122. Picardi, P.K.; Calegari, V.C.; De Oliveira Prada, P.; Contin Moraes, J.; Araujo, E.; Gomes Marcondes, M.C.C.; Ueno, M.; Carvalheira, J.B.C.; Velloso, L.A.; Abdalla Saad, M.J. Reduction of Hypothalamic Protein Tyrosine Phosphatase Improves Insulin and Leptin Resistance in Diet-Induced Obese Rats. Endocrinology, 2008, 149, 3870-3880.
123. Rousso-Noori, L.; Knobler, H.; Levy-Apter, E.; Kuperman, Y.; Neufeld-Cohen, A.; Keshet, Y.; Akepati, V.R.; Klinghoffer, R.A.; Chen, A.; Elson, A. Protein tyrosine phosphatase epsilon affects body weight by downregulating leptin signaling in a phosphorylation-dependent manner. Cell Metabolism, 2011, 13, 562-572.
124. Loh, K.; Fukushima, A.; Zhang, X.; Galic, S.; Briggs, D.; Enriori, P.J.; Simonds, S.; Wiede, F.; Reichenbach, A.; Hauser, C.; Sims, N.A.; Bence, K.K.; Zhang, S.; Zhang, Z.Y.; Kahn, B.B.; Neel, B.G.; Andrews, Z.B.; Cowley, M.A.; Tiganis, T. Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance. Cell Metab, 2011, 14, 684-699.
125. Bjorbaek, C.; Elmquist, J.K.; Frantz, J.D.; Shoelson, S.E.; Flier, J.S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Molecular cell, 1998, 1, 619-625.
126. Howard, J.K.; Cave, B.J.; Oksanen, L.J.; Tzameli, I.; Bjorbaek, C.; Flier, J.S. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med, 2004, 10, 734-738.
127. Mori, H.; Hanada, R.; Hanada, T.; Aki, D.; Mashima, R.; Nishinakamura, H.; Torisu, T.; Chien, K.R.; Yasukawa, H.; Yoshimura, A. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med, 2004, 10, 739-743.
128. Zhang, R.; Dhillon, H.; Yin, H.; Yoshimura, A.; Lowell, B.B.; Maratos-Flier, E.; Flier, J.S. Selective inactivation of Socs3 in SF1 neurons improves glucose homeostasis without affecting body weight. Endocrinology, 2008, 149, 5654-5661.
129. Kievit, P.; Howard, J.K.; Badman, M.K.; Balthasar, N.; Coppari, R.; Mori, H.; Lee, C.E.; Elmquist, J.K.; Yoshimura, A.; Flier, J.S. Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metab, 2006, 4, 123-132.
130. Zhang, S.; Zhang, Z.-Y. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discovery Today, 2007, 12, 373-381.
131. Guo, X.-L.; Shen, K.; Wang, F.; Lawrence, D.S.; Zhang, Z.-Y. Probing the Molecular Basis for Potent and Selective Proteintyrosine Phosphatase 1B Inhibition. Journal of Biological Chemistry, 2002, 277, 41014-41022.
132. Shen, K.; Keng, Y.-F.; Wu, L.; Guo, X.-L.; Lawrence, D.S.; Zhang, Z.-Y. Acquisition of a Specific and Potent PTP1B Inhibitor from a Novel Combinatorial Library and Screening Procedure. Journal of Biological Chemistry, 2001, 276, 47311-47319.
133. Bleasdale, J.E.; Ogg, D.; Palazuk, B.J.; Jacob, C.S.; Swanson, M.L.; Wang, X.-Y.; Thompson, D.P.; Conradi, R.A.; Mathews, W.R.; Laborde, A.L.; Stuchly, C.W.; Heijbel, A.; Bergdahl, K.; Bannow, C.A.; Smith, C.W.; Svensson, C.; Liljebris, C.; Schostarez, H.J.; May, P.D.; Stevens, F.C.; Larsen, S.D. Small Molecule Peptidomimetics Containing a Novel Phosphotyrosine Bioisostere Inhibit Protein Tyrosine Phosphatase 1B and Augment Insulin Action‡. Biochemistry, 2001, 40, 5642-5654.
134. Iversen, L.F.; Andersen, H.S.; Branner, S.; Mortensen, S.B.; Peters, G.H.; Norris, K.; Olsen, O.H.; Jeppesen, C.B.; Lundt, B.F.; Ripka, W.; Møller, K.B.; Møller, N.P.H. Structure-based Design of a Low Molecular Weight, Nonphosphorus, Nonpeptide, and Highly Selective Inhibitor of Protein-tyrosine Phosphatase 1B. Journal of Biological Chemistry, 2000, 275, 10300-10307.
135. Haque, A.; Andersen, Annik N.; Salmeen, A.; Barford, D.; Tonks, Nicholas k. Conformation-Sensing Antibodies Stabilize the Oxidized Form of PTP1B and Inhibit Its Phosphatase Activity. Cell, 2011, 147, 185-198.
136. Lantz, K.A.; Hart, S.G.E.; Planey, S.L.; Roitman, M.F.; Ruiz-White, I.A.; Wolfe, H.R.; Mclane, M.P. Inhibition of PTP1B by Trodusquemine (MSI-1436) Causes Fat-specific Weight Loss in Diet-induced Obese Mice. Obesity, 2010, 18, 1516-1523.
137. Ren, D.; Zhou, Y.; Morris, D.; Li, M.; Li, Z.; Rui, L. Neuronal SH2B1 is essential for controlling energy and glucose homeostasis. The Journal of Clinical Investigation, 2007, 117, 397-406.
138. Trevaskis, J.L.; Parkes, D.G.; Roth, J.D. Insights into amylin-leptin synergy. Trends in Endocrinology and Metabolism, 2010, 21, 473-479.
139. Roth, J.D.; Roland, B.L.; Cole, R.L.; Trevaskis, J.L.; Weyer, C.; Koda, J.E.; Anderson, C.M.; Parkes, D.G.; Baron, A.D. Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies. Proceedings of the National Academy of Sciences, 2008, 105, 7257-7262.
140. Trevaskis, J.L.; Coffey, T.; Cole, R.; Lei, C.; Wittmer, C.; Walsh, B.; Weyer, C.; Koda, J.; Baron, A.D.; Parkes, D.G.; Roth, J.D. Amylin-Mediated Restoration of Leptin esponsiveness in Diet-Induced Obesity: Magnitude and Mechanisms. Endocrinology, 2008, 149, 5679-5687.
141. Trevaskis, J.L.; Lei, C.; Koda, J.E.; Weyer, C.; Parkes, D.G.; Roth, J.D. Interaction of Leptin and Amylin in the Long-term Maintenance of Weight Loss in Diet-induced Obese Rats. Obesity,2009,18, 21-26.
142. Kusakabe, T.; Ebihara, K.; Sakai, T.; Miyamoto, L.; Aotani, D.; Yamamoto, Y.; Yamamoto-Kataoka, S.; Aizawa-Abe, M.; Fujikura, J.; Hosoda, K.; Nakao, K. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice. American Journal of Physiology -Endocrinology And Metabolism, 2012, 302, E924-E931.
143. Müller, T.D.; Sullivan, L.M.; Habegger, K.; Yi, C.-X.; Kabra, D.; Grant, E.; Ottaway, N.; Krishna, R.; Holland, J.; Hembree, J.; Perez-Tilve, D.; Pfluger, P.T.; Deguzman, M.J.; Siladi, M.E.; Kraynov, V.S.; Axelrod, D.W.; Dimarchi, R.; Pinkstaff, J.K.; Tschöp, M.H. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. Journal of Peptide Science, 2012, 18, 383-393.
144. Hung, H.Y.; Qian, K.; Morris-Natschke, S.L.; Hsu, C.S.; Lee, K.H. Recent discovery of plant-derived anti-diabetic natural products. Natural product reports, 2012, 29, 580-606.
145. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B.; Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425, 191-196.
146. Wood, J.G.; Rogina, B.; Lavu, S.; Howitz, K.; Helfand, S.L.; Tatar, M.; Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 2004, 430, 686-689.
147. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram, D.K.; De Cabo, R.; Sinclair, D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444, 337-342.
148. Ramadori, G.; Gautron, L.; Fujikawa, T.; Vianna, C.R.; Elmquist, J.K.; Coppari, R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology, 2009, 150, 5326-5333.
149. Ramadori, G.; Lee, C.E.; Bookout, A.L.; Lee, S.; Williams, K.W.; Anderson, J.; Elmquist, J.K.; Coppari, R. Brain SIRT1: Anatomical Distribution and Regulation by Energy Availability. J Neurosci, 2008, 28, 9989-9996.
150. Ramadori, G.; Fujikawa, T.; Anderson, J.; Berglund, Eric d.; Frazao, R.; Michán, S.; Vianna, Claudia r.; Sinclair, David a.; Elias, Carol f.; Coppari, R. SIRT1 Deacetylase in SF1 Neurons Protects against Metabolic Imbalance. Cell Metabolism, 2011, 14, 301-312.
151. Coppari, R. Metabolic actions of hypothalamic SIRT1. Trends in Endocrinology and Metabolism, 2012, 23, 179-185.
152. Cota, D.; Proulx, K.; Smith, K.A.; Kozma, S.C.; Thomas, G.; Woods, S.C.; Seeley, R.J. Hypothalamic mTOR signaling regulates food intake. Science, 2006, 312, 927-930.
153. Donato, J., Jr.; Pedrosa, R.G.; Cruzat, V.F.; Pires, I.S.; Tirapegui, J. Effects of leucine supplementation on the body composition and protein status of rats submitted to food restriction. Nutrition, 2006, 22, 520-527.
154. Vianna, D.; Resende, G.F.T.; Torres-Leal, F.L.; Pantaleão, L.C.; Donato Jr, J.; Tirapegui, J. Long-term leucine supplementation reduces fat mass gain without changing body protein status of aging rats. Nutrition, 2012, 28, 182-189.
155. Zhang, Y.; Guo, K.; Leblanc, R.E.; Loh, D.; Schwartz, G.J.; Yu, Y.H. Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. Diabetes, 2007, 56, 1647-1654.
156. Ropelle, E.R.; Pauli, J.R.; Fernandes, M.F.A.; Rocco, S.A.; Marin, R.M.; Morari, J.; Souza, K.K.; Dias, M.M.; Gomes-Marcondes, M.C.; Gontijo, J.a.R.; Franchini, K.G.; Velloso, L.A.; Saad, M.J.A.; Carvalheira, J.B.C. A Central Role for Neuronal AMP-Activated Protein Kinase (AMPK) and Mammalian Target of Rapamycin (mTOR) in High-Protein Diet-Induced Weight Loss. Diabetes, 2008, 57, 594-605.
157. Donato Jr., J.; Frazão, R.; Elias, C.F. The PI3K signaling pathway mediates the biological effects of leptin. Arquivos Brasileiros de Endocrinologia & Metabologia, 2010, 54, 591-602.
158. Chirumbolo, S. Quercetin in Cancer Prevention and Therapy. Integrative cancer therapies, 2012,
159. Kim, J.H.; Kang, M.J.; Choi, H.N.; Jeong, S.M.; Lee, Y.M.; Kim, J.I. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr Res Pract, 2011, 5, 107-111.
160. Claret, M.; Smith, M.A.; Batterham, R.L.; Selman, C.; Choudhury, A.I.; Fryer, L.G.; Clements, M.; Al-Qassab, H.; Heffron, H.; Xu, A.W.; Speakman, J.R.; Barsh, G.S.; Viollet, B.; Vaulont, S.; Ashford, M.L.; Carling, D.; Withers, D.J. AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J Clin Invest, 2007, 117, 2325-2336.
161. Martin, T.L.; Alquier, T.; Asakura, K.; Furukawa, N.; Preitner, F.; Kahn, B.B. Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J Biol Chem, 2006, 281, 18933-18941.
162. Minokoshi, Y.; Alquier, T.; Furukawa, N.; Kim, Y.B.; Lee, A.; Xue, B.; Mu, J.; Foufelle, F.; Ferre, P.; Birnbaum, M.J.; Stuck, B.J.; Kahn, B.B. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature, 2004, 428, 569-574.
163. Ryan, K.K.; Li, B.; Grayson, B.E.; Matter, E.K.; Woods, S.C.; Seeley, R.J. A role for central nervous system PPAR-[gamma] in the regulation of energy balance. Nat Med, 2011, 17, 623-626.
164. Pu, P.; Wang, X.A.; Salim, M.; Zhu, L.H.; Wang, L.; Chen, K.J.; Xiao, J.F.; Deng, W.; Shi, H.W.; Jiang, H.; Li, H.L. Baicalein, a natural product, selectively activating AMPKalpha(2) and ameliorates metabolic disorder in diet-induced mice. Mol Cell Endocrinol, 2012.